Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus FLUDARABINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus FLUDARABINE PHOSPHATE.
ADRUCIL vs FLUDARABINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
Fludarabine phosphate is a purine analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to apoptosis in lymphocytes.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
25 mg/m2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
None Documented
None Documented
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Terminal half-life of 2-fluoro-ara-A is approximately 20 hours (range 10–30 hours). Clinical context: accumulation occurs with repeated dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Renal excretion of the active metabolite 2-fluoro-ara-A accounts for approximately 60% of drug elimination. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antimetabolite
Antimetabolite